Rosetta Genomics to Present Multiple Posters at the American Association of Cancer Researchas (AACR) 101st Annual Meeting

Posted: April 15, 2010 at 4:56 am

Story Summary: (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Researchs (AACR) 101stAnnual Meeting to be held at the Walter E. Washington Convention Center in Washington, D. C. from April 17-21, 2010. microRNAs as a powerful diagnostic tool for the differential diagnosis of kidney tumorsThe posters will include data on Rosetta Genomics unique microRNA-based technologies and how they may be applied to develop objective and standardized diagnostic tests for cancer. It has been suggested that their small size (19-21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. miRview squamousaccurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain targeted therapies. This test can be used to rule out mesothelioma in patients diagnosed with a tumor in the lung or pleura, who may have been exposed to asbestos in the past. miRview tests are designed to provide objective diagnostic data; it is the treating physicians responsibility to diagnose and administer the appropriate treatment. The companys tests are now being offered through distributors around the globe. The companys first three microRNA-based tests, miRview squamous, miRview mets and miRview meso, are commercially available through its Philadelphia-based CAP accredited, CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journals Technology Innovation Awards in the medical/biotech category. To learn more, please visit www. rosettagenomics. Various statements in this release concerning Rosettas future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Various statements in this release concerning Rosettas future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In addition, any forward-looking statements represent Rosettas views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. In addition, any forward-looking statements represent Rosettas views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date….Read the Full Story

Related posts:

  1. Rosetta Genomics to Give Oral Presentation on Colon Cancer Screening Diagnostic at AACR Annual Meeting
  2. Rosetta Genomics Announces Publication of the Development and Validation Process of miRviewaC/ mets in Modern Pathology
  3. Rosetta Genomics Strengthens MicroRNA Intellectual Property Position with Receipt of Additional Patent


Related Post

Comments are closed.

Archives